#Australia #Sydney #SPRIM Global Investments #Mentara Therapeutics #PDE10A Inhibitor

Introduction

Mentara Therapeutics is making waves in the field of neuropsychology with the launch of MTA-304, a novel PDE10A inhibitor poised to enter Phase 2 clinical trials aimed at treating levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. Backed by SPRIM Global Investments and having acquired EM-221 from EuMentis Therapeutics, Mentara is geared up to address the significant unmet need for effective treatments for dyskinesia, a challenging side effect of long-term levodopa treatment.

Background on Parkinson's Disease and Levodopa

Parkinson's disease is a neurodegenerative disorder characterized by a range of motor and non-motor symptoms, most notably tremors, stiffness, and bradykinesia. Levodopa remains the gold standard for managing Parkinson’s symptoms, providing significant benefits to patients. However, prolonged use often leads to LID, which impacts approximately 40-50% of patients within four to six years. Unfortunately, treatment options for LID are scarce, with amantadine being the sole FDA-approved drug, often curtailed by side effects that include hallucinations, dizziness, and swelling.

The Promise of MTA-304

MTA-304, previously known as EM-221, is a second-generation PDE10A inhibitor that has shown promise in preliminary studies. The drug’s potential was evaluated through three Phase 1 studies involving 86 participants, where it exhibited a favorable safety and tolerability profile. Moreover, preclinical testing in animal models demonstrates MTA-304's capability to decrease dyskinesia by up to 40% without compromising the beneficial effects of levodopa. In comparative analyses against amantadine, MTA-304 showcased superior efficacy.

Frank Stonebanks, the CEO of Mentara Therapeutics, remarked on the significance of MTA-304: "People with Parkinson's shouldn't have to trade symptom control for dyskinesia. MTA-304 has a clean Phase 1 package and strong preclinical data in LID." This reinforces the company's commitment to deliver a potent treatment that ensures better quality of life for patients.

Mentara Therapeutics: Leadership and Future Directions

Mentara Therapeutics is spearheaded by Frank Stonebanks, who brings over 25 years of experience in biotech and venture capital. His leadership at EuMentis set the stage for this promising transition to Mentara, leveraging a solid foundation built on past achievements, including raising significant capital for drug development and overseeing a Phase 3 program.

As Mentara navigates the complexities of bringing MTA-304 to market, the company's focus will remain on enhancing the health and well-being of individuals affected by neuropsychiatric disorders. The planned Phase 2 study is expected to commence in early 2027, allowing the company to dig deeper into the viability and effectiveness of MTA-304.

Industry Impact and Collaborative Efforts

The backing from SPRIM Global Investments, a reputable life sciences venture capital firm, reinforces the potential of Mentara’s endeavors. "We are thrilled to back Mentara Therapeutics," stated Dr. Michael Shleifer, Co-Founder and Managing Partner of SPRIM, emphasizing the right timing for such an innovation in the industry.

In addition, under the acquisition agreement, EuMentis shareholders will transition to becoming stakeholders in Mentara, indicating a collaborative foundation for future growth.

Conclusion

As Mentara Therapeutics embarks on this journey with MTA-304, the hope is not only to provide an innovative solution for LID but also to redefine the standard of care for patients living with Parkinson's disease. By bridging the gap between current treatment shortcomings and patient needs, Mentara is set to impact the lives of countless individuals who struggle with the debilitating effects of dyskinesia. For more information, visit Mentara Therapeutics.